About Vor Biopharma Inc.
https://www.vorbio.comVor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.
CEO
Robert Ang MBBS
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-09-19 | Reverse | 1:20 |
ETFs Holding This Stock
Summary
Showing Top 3 of 21
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Stifel
Buy
Baird
Outperform
Oppenheimer
Outperform
JP Morgan
Overweight
JMP Securities
Market Perform
Grade Summary
Showing Top 6 of 7
Price Target
Institutional Ownership
COWEN AND COMPANY, LLC
Shares:1.22M
Value:$18.03M
JOHNSON & JOHNSON INNOVATION - JJDC, INC.
Shares:1.07M
Value:$15.87M
BLACKROCK INC.
Shares:497.7K
Value:$7.35M
Summary
Showing Top 3 of 10
About Vor Biopharma Inc.
https://www.vorbio.comVor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $28.11M ▼ | $-812.68M ▲ | 0% | $-121.63 ▲ | $-812.68M ▼ |
| Q2-2025 | $0 | $274.28M ▲ | $-1.57B ▼ | 0% | $-251.2 ▼ | $-241.51M ▼ |
| Q1-2025 | $0 | $33.29M ▲ | $-32.49M ▼ | 0% | $-5.2 ▲ | $-32.47M ▼ |
| Q4-2024 | $0 | $30.45M ▲ | $-30.71M ▼ | 0% | $-9 ▼ | $-29.85M ▼ |
| Q3-2024 | $0 | $28.51M | $-27.56M | 0% | $-8 | $-27.66M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $170.46M ▼ | $176.24M ▼ | $2.4B ▲ | $-2.23B ▼ |
| Q2-2025 | $200.56M ▲ | $205.37M ▲ | $1.71B ▲ | $-1.51B ▼ |
| Q1-2025 | $60.03M ▼ | $109.31M ▼ | $43.24M ▼ | $66.07M ▼ |
| Q4-2024 | $91.93M ▲ | $142.89M ▲ | $46.23M ▲ | $96.66M ▲ |
| Q3-2024 | $62.81M | $115.99M | $43.04M | $72.95M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-812.68M ▲ | $-53.66M ▼ | $-244K ▼ | $21.55M ▼ | $-32.52M ▼ | $-53.91M ▼ |
| Q2-2025 | $-1.57B ▼ | $-35.18M ▼ | $646K ▲ | $175.06M ▲ | $142.94M ▲ | $-35.34M ▼ |
| Q1-2025 | $-32.49M ▼ | $-31.07M ▼ | $-230K ▼ | $-606K ▼ | $-31.9M ▼ | $-31.3M ▼ |
| Q4-2024 | $-30.71M ▼ | $-24.06M ▼ | $-72K ▼ | $53.29M ▲ | $29.15M ▲ | $-24.14M ▼ |
| Q3-2024 | $-27.56M | $-23.29M | $-34K | $41K | $-23.28M | $-23.32M |
CEO
Robert Ang MBBS
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-09-19 | Reverse | 1:20 |
ETFs Holding This Stock
Summary
Showing Top 3 of 21
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Stifel
Buy
Baird
Outperform
Oppenheimer
Outperform
JP Morgan
Overweight
JMP Securities
Market Perform
Grade Summary
Showing Top 6 of 7
Price Target
Institutional Ownership
COWEN AND COMPANY, LLC
Shares:1.22M
Value:$18.03M
JOHNSON & JOHNSON INNOVATION - JJDC, INC.
Shares:1.07M
Value:$15.87M
BLACKROCK INC.
Shares:497.7K
Value:$7.35M
Summary
Showing Top 3 of 10